FILANA THERAPEUTICS, INC.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
FLNA$0.49+8.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(In thousands, except per share data)
| Years ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Operating expenses: | |||
| Research and development | $26,590 | $69,637 | $89,423 |
| General and administrative | 68,800 | 71,809 | 16,534 |
| Total operating expenses | 95,390 | 141,446 | 105,957 |
| Operating loss | (95,390) | (141,446) | (105,957) |
| Interest income | 4,620 | 8,510 | 7,833 |
| Other income (loss), net | (203) | 411 | 907 |
| Gain from change in fair value of warrant liabilities | — | 108,183 | — |
| Net loss | $(90,973) | $(24,342) | $(97,217) |
| Shares used in computing net loss per share, basic | 48,297 | 46,329 | 41,932 |
| Net loss per share, basic | $(1.88) | $(0.53) | $(2.32) |
| Numerator, diluted: | |||
| Net loss | $(90,973) | $(24,342) | $(97,217) |
| Adjustment for change in fair value of warrant liabilities | — | (43,793) | — |
| Adjusted numerator, diluted | $(90,973) | $(68,135) | $(97,217) |
| Shares used in computing net loss per share, diluted | 48,297 | 46,604 | 41,932 |
| Net loss per share, diluted | $(1.88) | $(1.46) | $(2.32) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.